Oxytocin and Labour: The Hormone That Starts Contractions

Oxytocin is the principal endocrine driver of human parturition. From the first tentative tightenings of the uterine wall to the powerful, rhythmic labour contractions that deliver a baby into the world, this nine-amino-acid peptide orchestrates the most dramatic physiological event in the human reproductive cycle. Understanding how oxytocin initiates, sustains, and modulates the process of childbirth is essential for clinicians, birth practitioners, and parents-to-be alike.

This article examines the molecular and neuroendocrine mechanisms by which oxytocin drives labour – from uterine receptor upregulation in late pregnancy, through the Ferguson reflex that amplifies contractions, to the clinical use of synthetic oxytocin (syntocinon) for the induction of labour. We also explore how the natural hormone differs from its pharmaceutical counterpart, and why the distinction matters for both mother and baby.

The Transition from Pregnancy to Labour: Preparing the Uterus

For most of pregnancy the uterus remains quiescent – a remarkable feat given the mechanical stretch imposed by a growing fetus. Progesterone dominance, low oxytocin receptor density, and nitric-oxide-mediated smooth muscle relaxation all contribute to uterine quiescence (Challis et al., 2000). The shift from quiescence to contractility requires a coordinated change in multiple hormonal axes.

Oxytocin Receptor Upregulation

The myometrium expresses the oxytocin receptor (OXTR), a G-protein-coupled receptor that triggers intracellular calcium release and smooth muscle contraction. Receptor density in the human myometrium increases approximately 100- to 200-fold between early pregnancy and term (Fuchs et al., 1984). This dramatic upregulation means the uterus becomes exquisitely sensitive to circulating oxytocin precisely when labour contractions are needed. The receptor increase is driven by rising oestrogen-to-progesterone ratios, prostaglandin E₂ signalling, and mechanical stretch of the uterine wall (Kimura et al., 1996).

Notably, OXTR expression increases in the fundal region of the uterus first, creating a gradient that favours top-down contractile waves – the coordinated pattern required for effective labour (Blanks et al., 2003). This spatial pattern explains why dysfunctional labour is often associated with disordered contractile patterns rather than insufficient oxytocin levels per se.

The Hormonal Cascade at Term

Oxytocin does not act alone. The initiation of labour involves a cascade of hormones including corticotropin-releasing hormone (CRH) from the placenta, a functional withdrawal of progesterone activity, rising oestradiol levels, and locally produced prostaglandins (PGE₂ and PGF₂α). Prostaglandins soften and ripen the cervix while simultaneously increasing myometrial gap-junction coupling, allowing the uterus to contract as a coordinated unit (Olson, 2003). The cuddle hormone oxytocin is thus part of a broader endocrine orchestra – arguably the conductor, but dependent on every section playing its part.

The Ferguson Reflex: A Positive Feedback Loop

The Ferguson reflex is one of the few examples of positive feedback in human physiology. As the fetal presenting part descends into the pelvis and presses against the cervix, mechanoreceptors in the cervical and vaginal walls transmit afferent signals via the pelvic nerve to the hypothalamus. The paraventricular and supraoptic nuclei respond by releasing pulsatile bursts of oxytocin from the posterior pituitary gland (Ferguson, 1941; Blanks & Bhargava, 2003).

Each pulse of oxytocin strengthens uterine contractions, which in turn push the fetus harder against the cervix, generating more sensory input and more oxytocin release. The Ferguson reflex thus creates an escalating cycle that drives labour to completion. The loop is broken only by delivery of the baby, which removes the cervical stimulus (Russell et al., 2003).

Pulsatile Release Pattern

The pattern of oxytocin release during labour is critically important. Natural oxytocin is secreted in discrete pulses from magnocellular neurones, with each pulse lasting approximately 30–60 seconds and occurring every 3–5 minutes during established labour (Fuchs et al., 1991). This pulsatile pattern prevents receptor desensitisation – a key consideration when comparing endogenous oxytocin with the continuous intravenous infusions used in clinical augmentation of labour.

Studies using serial blood sampling have shown that maternal plasma oxytocin concentrations do not increase dramatically across the first stage of labour; rather, it is the combination of pulsatile release, receptor upregulation, and increased myometrial sensitivity that drives progressive contractile force (Thornton et al., 1992). Peak oxytocin levels are reached during the second stage of labour and at the moment of delivery, when the Ferguson reflex is at its most intense.

Stages of Labour and Oxytocin’s Role

First Stage: Cervical Dilation

During the latent phase of labour, low-amplitude, irregular contractions begin to soften and thin (efface) the cervix. Oxytocin pulses are present but infrequent. As the active phase commences (typically at 4–6 cm cervical dilation), contraction frequency and intensity increase markedly. The molecular structure of oxytocin allows rapid binding and dissociation at the OXTR, permitting fine-tuned control of contractile force. Gap junctions between myometrial cells – upregulated by oestrogen and prostaglandins – enable the coordinated, fundally dominant contractions necessary for cervical dilation (Garfield et al., 1977).

Second Stage: Expulsion

The second stage of labour, from full cervical dilation to delivery of the infant, represents the peak of oxytocin activity. Maternal pushing efforts combine with maximal uterine contractile force. The Ferguson reflex is at its strongest, with oxytocin pulses occurring at their highest frequency and amplitude. Plasma oxytocin levels during this stage are typically 2–4 times higher than in early labour (Nissen et al., 1995).

Third Stage: Placental Delivery and Haemostasis

Following delivery of the baby, oxytocin continues to drive uterine contractions that separate and expel the placenta. Crucially, sustained myometrial contraction after placental delivery compresses the spiral arteries of the placental bed, providing the primary mechanism of haemostasis. This is why synthetic oxytocin (syntocinon) is routinely administered as part of active management of the third stage to prevent postpartum haemorrhage – the leading cause of maternal death worldwide (WHO, 2012).

Natural Oxytocin vs Synthetic Oxytocin in Childbirth

The distinction between endogenous (natural) oxytocin and exogenous (synthetic) oxytocin administered during induced labour is clinically significant. While syntocinon (the UK/European brand of synthetic oxytocin, known as pitocin in North America) is chemically identical to the endogenous peptide, the route and pattern of administration differ fundamentally from physiological release.

Induction of Labour with Synthetic Oxytocin

The induction of labour using intravenous syntocinon is one of the most common obstetric interventions worldwide. In the UK, approximately 30% of births involve some form of induction, with oxytocin infusion playing a central role (NICE, 2021). The typical protocol involves a continuous low-dose infusion titrated upward at 30-minute intervals until regular contractions are established (usually 3–4 contractions per 10 minutes).

However, continuous intravenous administration differs from the pulsatile bursts of natural oxytocin in several important ways:

• Receptor desensitisation: Continuous exposure can lead to OXTR internalisation and reduced myometrial sensitivity, paradoxically slowing labour progress (Robinson et al., 2003)
• Hyperstimulation: Excessive contraction frequency (tachysystole) can compromise uteroplacental blood flow and cause fetal distress
• Loss of pulsatility: The natural rhythm of contraction and relaxation may be disrupted, reducing the coordinated fundal dominance seen in spontaneous labour
• Absence of central effects: Intravenous oxytocin does not cross the blood–brain barrier in significant quantities, meaning the anxiolytic, analgesic, and bonding effects of centrally released oxytocin are absent (Uvnäs-Moberg et al., 2019)

Pulsatile Oxytocin Administration

Research into pulsatile intravenous oxytocin protocols has shown promise. A randomised controlled trial by Tribe et al. (2012) demonstrated that pulsed oxytocin administration resulted in fewer cases of uterine hyperstimulation and lower total oxytocin doses compared with continuous infusion, without increasing caesarean section rates. This approach more closely mimics the physiological pattern of release driven by the Ferguson reflex.

Augmentation of Labour

Augmentation of labour – the use of oxytocin to enhance contractions when spontaneous labour is progressing slowly – is distinct from induction. Guidelines recommend careful assessment before commencing oxytocin augmentation, as many cases of slow progress respond to simple measures such as upright positioning, ambulation, and amniotomy. The augmentation of labour with oxytocin carries the same risks of hyperstimulation and should be titrated with electronic fetal monitoring in place (ACOG, 2019).

Oxytocin, Endorphins, and Pain in Labour

Endogenous oxytocin release during spontaneous labour triggers a parallel release of β-endorphin, the body’s natural opioid. This neurohormonal coupling provides a degree of physiological analgesia during labour and contributes to the altered state of consciousness many labouring women describe during active labour and transition (Odent, 2001). The endorphin surge also promotes the sense of euphoria and heightened emotional receptivity that facilitates immediate mother–infant bonding after birth.

When synthetic oxytocin is used for pitocin induction or augmentation, this central endorphin co-release does not occur (because intravenous oxytocin does not penetrate the brain), which may partly explain why women receiving synthetic oxytocin report higher pain levels and are more likely to request epidural analgesia (Belghiti et al., 2013).

Oxytocin Antagonists: Stopping Premature Labour

Just as oxytocin drives labour at term, blocking its action can be therapeutically valuable in preterm labour. Atosiban is a selective oxytocin receptor antagonist licensed in Europe for the acute treatment of preterm labour between 24 and 33 weeks’ gestation. By competitively blocking OXTR, atosiban suppresses uterine contractions and can delay delivery by 48 hours – sufficient time to administer antenatal corticosteroids for fetal lung maturation (Worldwide Atosiban versus Beta-agonists Study Group, 2001).

Atosiban has a favourable side-effect profile compared with older tocolytics (beta-agonists and calcium channel blockers), largely because it is highly specific for OXTR and the structurally related vasopressin V₁ₐ receptor. For more detail on how this antagonist works, see our dedicated page on atosiban.

Clinical Considerations and Evidence-Based Practice

Monitoring and Safety

The use of synthetic oxytocin in labour requires careful monitoring. The half-life of intravenous oxytocin is approximately 3–5 minutes, meaning dose adjustments have a relatively rapid effect – but also that cessation does not immediately stop contractions, as downstream calcium signalling and prostaglandin release continue briefly. Continuous electronic fetal monitoring is recommended whenever oxytocin is infused, and protocols should specify clear criteria for dose reduction or cessation in the event of tachysystole or fetal heart rate abnormalities (RCOG, 2013).

Water Intoxication

Oxytocin has structural homology with vasopressin (antidiuretic hormone) and at high doses can activate renal V₂ receptors, causing water retention and hyponatraemia. Although rare at standard labour induction doses, prolonged high-dose infusions – particularly with hypotonic intravenous fluids – can cause clinically significant water intoxication. This is another reason for protocol-driven dose limits and careful fluid balance monitoring (Moen et al., 2009).

The Broader Context: Oxytocin Beyond Contractions

While this article focuses on the uterine effects of oxytocin in labour, it is important to recognise that the oxytocin released during birth has far-reaching effects. The same hormone that drives labour contractions also primes maternal bonding behaviour, initiates lactation via the milk let-down reflex, modulates the neonatal stress response, and shapes the early mother–infant relationship. For a broader perspective on oxytocin’s multifaceted roles, explore our overview of oxytocin or learn about its molecular structure.

Frequently Asked Questions

References

1. ACOG (2019). Practice Bulletin No. 107: Induction of labor. Obstetrics & Gynecology.
2. Belghiti, J. et al. (2013). Oxytocin during labour and risk of severe postpartum haemorrhage. BMJ, 343, d4165.
3. Blanks, A.M. et al. (2003). Myometrial function in prematurity. Best Practice & Research Clinical Obstetrics & Gynaecology, 17(2), 174–190.
4. Blanks, A.M. & Bhargava, S. (2003). The Ferguson reflex and uterine function. Reproduction, 125(5), 597–606.
5. Challis, J.R. et al. (2000). Endocrine and paracrine regulation of birth at term and preterm. Endocrine Reviews, 21(5), 514–550.
6. Ferguson, J.K.W. (1941). A study of the motility of the intact uterus at term. Surgery, Gynecology & Obstetrics, 73, 359–366.
7. Fuchs, A.R. et al. (1984). Oxytocin receptors and human parturition. Science, 215(4538), 1396–1398.
8. Fuchs, A.R. et al. (1991). Oxytocin secretory responses to cervical and vaginal stimulation during human parturition. American Journal of Obstetrics and Gynecology, 165(6), 1792–1801.
9. Garfield, R.E. et al. (1977). Gap junctions in the myometrium. American Journal of Physiology, 233(3), C168–C174.
10. Grobman, W.A. et al. (2018). Labor induction versus expectant management in low-risk nulliparous women (ARRIVE trial). New England Journal of Medicine, 379(6), 513–523.
11. Kimura, T. et al. (1996). Expression of the human oxytocin receptor in the human myometrium. Endocrinology, 137(2), 780–785.
12. Moen, V. et al. (2009). Hyponatremia complicating labour. BJOG, 116(3), 399–402.
13. NICE (2021). Inducing Labour: Clinical Guideline NG207. National Institute for Health and Care Excellence.
14. Nissen, E. et al. (1995). Oxytocin, prolactin, and cortisol levels in response to nursing. Psychoneuroendocrinology, 20(7), 681–692.
15. Odent, M. (2001). New reasons and new ways to study birth physiology. International Journal of Gynecology & Obstetrics, 75, S39–S45.
16. Olson, D.M. (2003). The role of prostaglandins in the initiation of parturition. Best Practice & Research Clinical Obstetrics & Gynaecology, 17(5), 717–730.
17. RCOG (2013). Monitoring during labour: Green-top Guideline No. 30. Royal College of Obstetricians and Gynaecologists.
18. Robinson, C. et al. (2003). Oxytocin receptor desensitisation. American Journal of Obstetrics and Gynecology, 188(2), 497–502.
19. Russell, J.A. et al. (2003). Brain preparations for maternity. Progress in Brain Research, 133, 1–38.
20. Thornton, S. et al. (1992). Plasma oxytocin during third stage of labour. BMJ, 305(6860), 1004–1005.
21. Tribe, R.M. et al. (2012). A randomised trial of pulsatile oxytocin administration. BJOG, 119(10), 1224–1233.
22. Uvnäs-Moberg, K. et al. (2019). Maternal plasma levels of oxytocin during physiological childbirth. BMC Pregnancy and Childbirth, 19, 285.
23. WHO (2012). WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. World Health Organization.
24. Worldwide Atosiban versus Beta-agonists Study Group (2001). Effectiveness and safety of atosiban. BJOG, 108(2), 133–142.